Ionis Pharmaceuticals (IONS) Non Operating Investment Income (2009 - 2026)

Ionis Pharmaceuticals' Non Operating Investment Income history runs 15 years deep, the most recent figure standing at $22.6 million for Q1 2026.

• On a quarterly basis, Non Operating Investment Income rose 1143.58% year-over-year to $22.6 million in Q1 2026; TTM through Mar 2026 was $35.0 million, a 573.42% increase from a year earlier, with the FY2025 full-year figure at $10.2 million, up 453.76% from the prior year.
• Non Operating Investment Income rose to $22.6 million in Q1 2026 per IONS's latest filing, from $788000.0 in the prior quarter.
• Across five years, Non Operating Investment Income topped out at $29.9 million in Q3 2025 and bottomed at -$18.3 million in Q2 2025.
• The 5-year median for Non Operating Investment Income is -$161000.0 (2023), against an average of $1.2 million.
• Across the five-year window, Non Operating Investment Income tumbled 1495.03% in 2024 and jumped 3302.5% in 2025, its largest moves.
• Year by year, Non Operating Investment Income stood at $3.3 million in 2022, then slumped by 104.9% to -$161000.0 in 2023, then tumbled by 1495.03% to -$2.6 million in 2024, then jumped by 130.69% to $788000.0 in 2025, then surged by 2765.86% to $22.6 million in 2026.
• Per Business Quant, the three latest IONS Non Operating Investment Income figures stand at $22.6 million (Q1 2026), $788000.0 (Q4 2025), and $29.9 million (Q3 2025).